Find and Pitch Jounalists, Get Your Story Covered

Tags: Novartis MHRA authorisation Ribociclib NATALEE Trial Breast Cancer

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Libtayo available in Scotland for cervical cancer patients - 2 months ago Novartis secures MHRA authorisation for ribociclib - 2 months ago CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients - 2 months ago EC approves Rybrevant with Lazcluze for advanced lung cancer - 4 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	FDA Approves Datroway for Pretreated Advanced Breast Cancer - 3 months ago Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 4 months ago Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma - 4 months ago FDA Approves Zanidatamab for Biliary Tract Cancer - 5 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 8 months ago Novel PARP1 Inhibitor Shows Promise in Breast Cancer - about 1 year ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - about 1 year ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - about 1 year ago Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone - about 1 year ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - over 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Adding Palbociclib to Standard Care Improved PFS in Triple-Positive Breast Cancer - 3 months ago Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - 4 months ago Regorafenib-Pembrolizumab Has 'Modest' Activity in HCC Post-Immunotherapy - 10 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - about 1 year ago Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma - over 1 year ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - over 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - over 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - over 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer - 4 months ago SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 4 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 10 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - about 1 year ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 10 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - about 1 year ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - about 1 year ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - about 1 year ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - over 1 year ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - over 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - over 1 year ago
7	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - about 1 year ago
8	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - about 1 year ago Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation - over 1 year ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - about 1 year ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - about 1 year ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - over 1 year ago MONALEESA Pooled Analyses Show Quality of Life Is Maintained in Elderly Patients Receiving Ribociclib, Endocrine Therapy - over 1 year ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - over 1 year ago Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma - over 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment - over 1 year ago ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer - over 1 year ago FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma - over 1 year ago FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer - over 1 year ago FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer - over 1 year ago FDA Grants Priority Review to Expand Indication for Bristol Myers Squibb’s Breyanzi in CLL, SLL - over 1 year ago

Journalists covering ribociclib